Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs

Li, Hongjiao; Wang, Yi; Yang, Fenfang; Feng, Shuang; Chang, Kaijing; Yu, Xinwen; Guan, Feng; Li, Xiang

doi:10.1016/j.redox.2023.102900

Cited by 2 publications

(2 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, upon LSC onset, BMMSCs have been shown to undergo severe reprogramming through various interconnected mechanisms, including leukaemia-secreted factors, EV mediation, and cell-to-cell interactions [22,58,114,115]. Most interestingly, BMMSCs isolated from patients with AML-but not acute lymphoblastic leukaemia (ALL), Hodgkin disease (HD), or non-Hodgkin lymphoma-showed both transient and prolonged abnormal biological properties compared with healthy donor counterparts [116].…”

Section: Bm Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

“…Illustrating this is increased secretion of IFN-γ triggered by the overexpression of the TWIST1 oncogene in many MDS and AML blasts [59]. Leukaemiasecreted IFN-γ seems to activate STAT1 signalling in BMMSCs, downregulating NAD(P)H quinone-oxidoreductase-1 (NQO1) redox enzymes, with a consequent increase in intracellular ROS generation [58]. Interestingly, this seems to favour BMMSCs to use OXPHOSrelated proteins, strongly inhibiting their osteogenic differentiation and promoting BMMSC senescence.…”

Section: Bm Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

See 1 more Smart Citation

Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression

Mendes,

Monteiro,

Neto

et al. 2024

IJMS

View full text Add to dashboard Cite

Acute myeloid leukaemia (AML) management remains a significant challenge in oncology due to its low survival rates and high post-treatment relapse rates, mainly attributed to treatment-resistant leukaemic stem cells (LSCs) residing in bone marrow (BM) niches. This review offers an in-depth analysis of AML progression, highlighting the pivotal role of extracellular vesicles (EVs) in the dynamic remodelling of BM niche intercellular communication. We explore recent advancements elucidating the mechanisms through which EVs facilitate complex crosstalk, effectively promoting AML hallmarks and drug resistance. Adopting a temporal view, we chart the evolving landscape of EV-mediated interactions within the AML niche, underscoring the transformative potential of these insights for therapeutic intervention. Furthermore, the review discusses the emerging understanding of endothelial cell subsets’ impact across BM niches in shaping AML disease progression, adding another layer of complexity to the disease progression and treatment resistance. We highlight the potential of cutting-edge methodologies, such as organ-on-chip (OoC) and single-EV analysis technologies, to provide unprecedented insights into AML–niche interactions in a human setting. Leveraging accumulated insights into AML EV signalling to reconfigure BM niches and pioneer novel approaches to decipher the EV signalling networks that fuel AML within the human context could revolutionise the development of niche-targeted therapy for leukaemia eradication.

show abstract

Section: Bm Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

Section: Bm Mesenchymal Stromal/stem Cellsmentioning

confidence: 99%

Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression

Mendes,

Monteiro,

Neto

et al. 2024

IJMS

View full text Add to dashboard Cite

show abstract

The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression

Cuevas,

Amigo,

Agurto

et al. 2024

Biomedicines

View full text Add to dashboard Cite

Acute myeloid leukemia (AML) is a diverse malignancy originating from myeloid progenitor cells, with significant genetic and clinical variability. Modern classification systems like those from the World Health Organization (WHO) and European LeukemiaNet use immunophenotyping, molecular genetics, and clinical features to categorize AML subtypes. This classification highlights crucial genetic markers such as FLT3, NPM1 mutations, and MLL-AF9 fusion, which are essential for prognosis and directing targeted therapies. The MLL-AF9 fusion protein is often linked with therapy-resistant AML, highlighting the risk of relapse due to standard chemotherapeutic regimes. In this sense, factors like the ZEB, SNAI, and TWIST gene families, known for their roles in epithelial–mesenchymal transition (EMT) and cancer metastasis, also regulate hematopoiesis and may serve as effective therapeutic targets in AML. These genes contribute to cell proliferation, differentiation, and extramedullary hematopoiesis, suggesting new possibilities for treatment. Advancing our understanding of the molecular mechanisms that promote AML, especially how the bone marrow microenvironment affects invasion and drug resistance, is crucial. This comprehensive insight into the molecular and environmental interactions in AML emphasizes the need for ongoing research and more effective treatments.

show abstract

Clonal MDS/AML cells with enhanced TWIST1 expression reprogram the differentiation of bone marrow MSCs

Cited by 2 publications

References 51 publications

Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression

Transforming the Niche: The Emerging Role of Extracellular Vesicles in Acute Myeloid Leukaemia Progression

The Role of Epithelial-to-Mesenchymal Transition Transcription Factors (EMT-TFs) in Acute Myeloid Leukemia Progression

Contact Info

Product

Resources

About